 MONMOUTH JUNCTION, N.J., Oct. 14, 2021 PRNewswire -- CytoSorbents Corporation NASDAQ: CTSO, a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor START double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb-ATRTM Antithrombotic Removal System for intraoperative removal of ticagrelor during cardiothoracic surgery. 